Disulfiram for Cocaine-Alcohol Abuse - 3

NCT ID: NCT00000278

Last Updated: 2020-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

1994-09-30

Study Completion Date

1999-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate disulfiram for cocaine-alcohol abuse.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol-Related Disorders Cocaine-Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Disulfiram

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Please contact site for information.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role collaborator

VA Connecticut Healthcare System

FED

Sponsor Role collaborator

Yale University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas R Kosten, M.D.

Role: PRINCIPAL_INVESTIGATOR

VA Connecticut Healthcare System

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

VA Connecticut Healthcare System

New Haven, Connecticut, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Biol Psy. 37: 560-563, 1995. NIDA Research Monograph, 174:138, 1997. Ther Drug Monograph, 18:460-464, 1996.

Reference Type BACKGROUND

Traccis F, Minozzi S, Trogu E, Vacca R, Vecchi S, Pani PP, Agabio R. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev. 2024 Jan 5;1(1):CD007024. doi: 10.1002/14651858.CD007024.pub3.

Reference Type DERIVED
PMID: 38180268 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P50DA009250

Identifier Type: NIH

Identifier Source: secondary_id

View Link

P50-09250-3

Identifier Type: -

Identifier Source: secondary_id

NIDA-09250-3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Mazindol for Cocaine Abuse - 2
NCT00000277 COMPLETED PHASE2
Aripiprazole to Reduce Cocaine Relapse
NCT00276874 COMPLETED PHASE1
Cocaine Use Reduction and Health
NCT03224546 COMPLETED NA
n-Acetylcysteine and Cocaine
NCT02141620 COMPLETED EARLY_PHASE1